Skye Bioscience, Inc. (NASDAQ: SKYE) had its price target lowered by analysts at Craig Hallum from $18.00 to $14.00. They now have a "buy" rating on the stock.
Skye Bioscience, Inc. (NASDAQ: SKYE) had its "outperform" rating re-affirmed by analysts at William Blair.
Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript [Seeking Alpha]
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update